These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 25764960)

  • 1. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products.
    Gilligan AM; Waycaster CR; Landsman AL
    J Wound Care; 2015 Mar; 24(3):149-56. PubMed ID: 25764960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Wound Closure Rates Using a Human Fibroblast-derived Dermal Substitute Versus a Fetal Bovine Collagen Dressing: A Retrospective Study.
    Fitzgerald RH; Sabolinski ML; Skornicki M
    Wound Manag Prev; 2019 Sep; 65(9):26-34. PubMed ID: 31702990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.
    Rice JB; Desai U; Ristovska L; Cummings AK; Birnbaum HG; Skornicki M; Margolis DJ; Parsons NB
    J Med Econ; 2015; 18(8):586-95. PubMed ID: 25786331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft.
    Sanders L; Landsman AS; Landsman A; Keller N; Cook J; Cook E; Hopson M
    Ostomy Wound Manage; 2014 Sep; 60(9):26-38. PubMed ID: 25211605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open-label trial.
    Motley TA; Gilligan AM; Lange DL; Waycaster CR; Dickerson JE
    J Foot Ankle Res; 2015; 8():7. PubMed ID: 25767565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context.
    Allenet B; Parée F; Lebrun T; Carr L; Posnett J; Martini J; Yvon C
    Diabetes Metab; 2000 Apr; 26(2):125-32. PubMed ID: 10804327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human fibroblast-derived dermal substitute: results from a treatment investigational device exemption (TIDE) study in diabetic foot ulcers.
    Warriner RA; Cardinal M;
    Adv Skin Wound Care; 2011 Jul; 24(7):306-11. PubMed ID: 21685733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of three adjunct cellular/tissue-derived products used in the management of chronic venous leg ulcers.
    Carter MJ; Waycaster C; Schaum K; Gilligan AM
    Value Health; 2014 Dec; 17(8):801-13. PubMed ID: 25498775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective, Randomized, Blinded, Controlled Trial Comparing Transdermal Continuous Oxygen Delivery to Moist Wound Therapy for the Treatment of Diabetic Foot Ulcers.
    Driver VR; Reyzelman A; Kawalec J; French M
    Ostomy Wound Manage; 2017 Apr; 63(4):12-28. PubMed ID: 28448266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-Effectiveness Analysis Comparing Single-use and Traditional Negative Pressure Wound Therapy to Treat Chronic Venous and Diabetic Foot Ulcers.
    Kirsner RS; Delhougne G; Searle RJ
    Wound Manag Prev; 2020 Mar; 66(3):30-36. PubMed ID: 32294054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers.
    Ananian CE; Dhillon YS; Van Gils CC; Lindsey DC; Otto RJ; Dove CR; Pierce JT; Saunders MC
    Wound Repair Regen; 2018 May; 26(3):274-283. PubMed ID: 30098272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Comparative Effectiveness of a Human Fibroblast Dermal Substitute versus a Dehydrated Human Amnion/Chorion Membrane Allograft for the Treatment of Diabetic Foot Ulcers in a Real-world Setting.
    Kraus I; Sabolinski ML; Skornicki M; Parsons NB
    Wounds; 2017 May; 29(5):125-132. PubMed ID: 28570252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of using adjunctive porcine small intestine submucosa tri-layer matrix compared with standard care in managing diabetic foot ulcers in the US.
    Guest JF; Weidlich D; Singh H; La Fontaine J; Garrett A; Abularrage CJ; Waycaster CR
    J Wound Care; 2017 Jan; 26(Sup1):S12-S24. PubMed ID: 28105902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis.
    Frykberg RG; Cazzell SM; Arroyo-Rivera J; Tallis A; Reyzelman AM; Saba F; Warren L; Stouch BC; Gilbert TW
    J Wound Care; 2016 Jul; 25(Sup7):S18-S25. PubMed ID: 29027848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics for treatment of diabetic foot ulcers: a cost-effectiveness analysis of eight skin substitutes.
    Samsell B; McLean J; Cazzell S; Dorsch K; Moyer PM; Moore M
    J Wound Care; 2019 Sep; 28(Sup9):S14-S26. PubMed ID: 31509489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total contact casting combined with human fibroblast-derived dermal tissue in 15 DFU patients.
    Kashefsky H; Marston W
    J Wound Care; 2012 May; 21(5):236, 238, 240, 242-3. PubMed ID: 22584742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of a human fibroblast-derived dermal substitute and a viable cryopreserved placental membrane for the treatment of diabetic foot ulcers.
    Sabolinski ML; Capotorto JV
    J Comp Eff Res; 2019 Oct; 8(14):1229-1238. PubMed ID: 31407588
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
    Lantis JC; Boone D; Gendics C; Todd G
    Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of diabetic foot ulcers with dehydrated amniotic membrane allograft: a prospective case series.
    Abdo RJ
    J Wound Care; 2016 Jul; 25(Sup7):S4-S9. PubMed ID: 29027851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of wound duration on diabetic foot ulcer healing: evaluation of a new sucrose octasulfate wound dressing.
    Lobmann R; Grünerbel A; Lawall H; Lüdemann C; Morbach S; Tigges W; Völkel L; Rychlik RP
    J Wound Care; 2020 Oct; 29(10):543-551. PubMed ID: 33052796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.